Regeneron Pharmaceuticals, Inc.
Feb 25, 2010

Regeneron Announces Participation in a Panel Discussion at RBC Capital Markets Healthcare Conference

TARRYTOWN, N.Y., Feb 25, 2010 /PRNewswire via COMTEX News Network/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will participate in a webcast panel discussion on the topic "Building a Proprietary and Partnered Pipeline of Antibodies" at the RBC Capital Markets Healthcare Conference on Wednesday, March 3, 2010. The panel discussion will be broadcast live at 2:05 p.m. Eastern Time and may be accessed through the Company's web site,, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through April 2, 2010.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST(R) (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, age-related macular degeneration, and certain cancers. Additional therapeutic candidates are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron's web site at

    Contact Information:

    Peter Dworkin                      Laura Lindsay
    Investor Relations                 Media Relations
    914.345.7640                       914.345.7800

SOURCE Regeneron Pharmaceuticals, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved